Hydrops fetalis: definition, evaluation, and management
Hydrops fetalis is abnormal fetal fluid accumulation. It is classically diagnosed when fluid is present in two or more fetal compartments. A single effusion may represent a related hydrops fetalis spectrum condition and should be evaluated when a systemic fetal, placental, infectious, or genetic process is suspected.
Updated: June 2026. Content incorporates SMFM Consult Series #75, which replaces SMFM Clinical Guideline #7.
On this page
Definition and ultrasound criteria
Hydrops fetalis is the presence of abnormal fluid collections in two or more fetal compartments:
Ascites Pleural effusion Pericardial effusion >2–3 mm Generalized skin edema >5 mm
Common associated findings include placentomegaly and polyhydramnios, although these are not formal diagnostic criteria. SMFM defines placentomegaly as placental thickness ≥4 cm in the second trimester or ≥6 cm in the third trimester, and polyhydramnios as deepest vertical pocket ≥8 cm or amniotic fluid index ≥24 cm.
Why hydrops develops
Most causes of NIHF produce fetal edema or effusions by one or more final common pathways: cardiac failure, increased venous pressure, impaired lymphatic return, increased capillary permeability, decreased oncotic pressure, or severe anemia with high-output failure.
Evaluation algorithm when one or more fetal effusions are detected
Confirm the finding
Document the fluid compartment(s), severity, fetal viability, gestational age, placental thickness, amniotic fluid volume, fetal growth, and whether a single focal lesion explains the fluid collection.
Rule out immune hydrops
Review maternal blood type and Rh(D) status and repeat antibody screen/indirect Coombs test. If alloimmunization is present, manage as immune hydrops/fetal anemia.
Detailed ultrasound + Doppler
Perform a detailed anatomic survey of fetus, placenta, and cord; assess fetal growth and amniotic fluid; obtain MCA peak systolic velocity to screen for fetal anemia, regardless of whether structural anomalies are present.
Fetal echocardiography and rhythm assessment
Evaluate cardiac anatomy, function, venous Doppler, cardiomyopathy, tumors, tachyarrhythmia, bradyarrhythmia, or heart block. Consider extended rhythm monitoring when intermittent arrhythmia is suspected.
Maternal and infectious evaluation
Review CBC, MCV, hemoglobin electrophoresis/carrier screening, syphilis testing, and exposure history. Consider parvovirus B19, CMV, toxoplasmosis, and other testing based on presentation. Evaluate for fetomaternal hemorrhage with Kleihauer-Betke or flow cytometry, especially when MCA-PSV is elevated or there is trauma/abruption concern.
Fetal diagnostic testing
Offer diagnostic testing. SMFM recommends chromosomal microarray with or without karyotype for all pregnancies with one or more fetal effusions. If infection is in the differential, perform PCR studies on amniotic fluid or fetal sample when appropriate.
Exome/genome sequencing when initial testing is nondiagnostic
Offer exome or genome sequencing after nondiagnostic CMA/karyotype when no other etiology is suspected. Concurrent sequencing may be reasonable when aneuploidy risk is low, a single-gene disorder is strongly suspected, or time-sensitive management decisions are needed.
Etiology-directed management and counseling
Discuss prognosis, recurrence risk, maternal risks including mirror syndrome, fetal therapy options when available, neonatal resuscitation goals, and all pregnancy management options.
Useful site links: MCA PSV calculator | CPAM/CVR calculator | Ascites glossary
Etiologic classification of nonimmune hydrops fetalis
| Category | Examples | Typical mechanism | Approximate frequency reported by SMFM |
|---|---|---|---|
| Multiple anomalies / syndromic / genetic | Aneuploidy, RASopathies, Noonan spectrum, lymphatic dysplasias, metabolic disorders, fetal akinesia/neuromuscular syndromes | Lymphatic dysplasia, structural anomalies, cardiac disease, low oncotic pressure | 19%–53% for multiple anomalies/syndromic/genetic; aneuploidy 13%–30%; RASopathies 7%–8% |
| Cardiovascular | Structural heart disease, cardiomyopathy, cardiac tumor, supraventricular tachycardia, atrial flutter, congenital heart block | Low-output or high-output heart failure, impaired filling, venous congestion | 8%–20% |
| Lymphatic | Cystic hygroma, congenital lymphatic dysplasia, Milroy disease, lymphedema-distichiasis, RASopathy-related lymphatic disease | Impaired lymphatic return | 6%–10%; other congenital lymphatic anomalies 2%–4% |
| Infectious | Parvovirus B19, CMV, syphilis, toxoplasmosis; others as clinically indicated | Anemia, myocarditis, hepatic dysfunction, increased capillary permeability | 7%–8% |
| Pulmonary / thoracic | CPAM, bronchopulmonary sequestration, chylothorax, congenital diaphragmatic hernia, high airway obstruction | Mass effect, venous return impairment, pulmonary hypoplasia risk | 5%–6%; NIHF reported in about 6%–7% of fetuses with CPAM |
| Hematologic / fetal anemia | Alpha-thalassemia major, fetomaternal hemorrhage, parvovirus anemia, hereditary anemias | High-output cardiac failure from severe anemia | 0%–10%; alpha-thalassemia major is an important cause in at-risk ancestry groups |
| Placental / cord / tumor | Chorioangioma, sacrococcygeal teratoma, vein of Galen aneurysm, hepatic hemangioma, umbilical vascular lesions | High-output failure, arteriovenous shunting, venous obstruction | Chorioangioma about 2%; extra-thoracic tumor 0%–1% |
| Monochorionic twin complications | Twin-twin transfusion syndrome, TAPS, TRAP sequence | Recipient volume overload, donor anemia, acardiac twin perfusion load | TTTS 4%–5% |
| Genitourinary / gastrointestinal / low oncotic pressure | Congenital nephrotic syndrome, ruptured bladder/urinoma, meconium peritonitis, intestinal obstruction, hepatic disease | Specific fluid collection vs systemic edema; protein loss; impaired venous return | Genitourinary 0%–2%; gastrointestinal 0%–1% |
Frequency estimates are approximate and may overlap because next-generation sequencing can identify genetic disorders that also explain fetal structural findings.
Treatable or potentially modifiable causes
| Finding or suspected cause | Evaluation clue | Potential treatment or referral |
|---|---|---|
| Fetal anemia | MCA-PSV ≥1.5 MoM; alloimmunization, parvovirus, fetomaternal hemorrhage, alpha-thalassemia | Percutaneous umbilical blood sampling when indicated; intrauterine transfusion in appropriate candidates |
| Tachyarrhythmia | Sustained SVT or atrial flutter; hydrops worsens prognosis | Maternal transplacental antiarrhythmic therapy and fetal cardiology/MFM management |
| Congenital heart block | Fetal bradycardia, maternal SSA/SSB antibodies, structural heart disease | Fetal cardiology; etiology-specific counseling and surveillance |
| Large pleural effusion / chylothorax | Mediastinal shift, hydrops, pulmonary compression | Fetal therapy consultation; thoracentesis or thoracoamniotic shunt in selected cases |
| CPAM or thoracic mass | Large lesion, mediastinal shift, CVR elevation, hydrops | Fetal treatment center referral; consider corticosteroids or procedure depending on lesion type and gestational age |
| Syphilis | Positive maternal serology | Penicillin treatment according to pregnancy stage and CDC/obstetric guidance |
| Monochorionic twin complication | TTTS/TAPS/TRAP findings | Referral to fetal therapy center; laser or cord occlusion in selected cases |
| Placental chorioangioma or vascular tumor | Large vascular placental mass; high-output physiology | Fetal therapy center evaluation when hydrops, anemia, or high-output failure develops |
Maternal risks: mirror syndrome and preeclampsia-like disease
Mirror syndrome is a maternal complication in which the pregnant patient develops edema and a preeclampsia-like picture that “mirrors” fetal and placental edema. SMFM reports mirror syndrome in approximately 8%–38% of pregnancies with NIHF, with estimates limited by small study sizes.
Counseling and prognosis
- Prognosis depends primarily on the underlying cause, gestational age, number and severity of effusions, presence of structural anomalies, fetal anemia, arrhythmia, genetic diagnosis, and whether fetal therapy is available.
- A single effusion and generalized NIHF should not be assumed to have the same prognosis; however, the diagnostic evaluation often overlaps.
- Diagnostic testing may clarify recurrence risk, especially for aneuploidy, autosomal recessive metabolic disease, RASopathy, hereditary anemia, and lymphatic disorders.
- If diagnostic testing is declined, noninvasive screening may be considered, but it does not replace diagnostic testing and has limited scope.
- Neonatology, pediatric cardiology, genetics, infectious disease, hematology, pediatric surgery, or fetal therapy consultation should be individualized to the suspected etiology.
Antepartum and delivery considerations
- Ongoing surveillance is individualized by gestational age, etiology, progression, treatment options, and goals of care.
- Monitor the mother for preeclampsia, mirror syndrome, respiratory symptoms, and worsening edema.
- Delivery timing should be individualized. SMFM recommends reserving preterm delivery for obstetric indications such as preeclampsia or mirror syndrome, preterm labor, PPROM, new or worsening NIHF, or when maternal or fetal risks of continued pregnancy exceed the risks of delivery.
- Give antenatal corticosteroids when preterm delivery is anticipated within 7 days, neonatal resuscitation is desired, and neonatal resuscitation would be offered.
- Cesarean delivery should be for standard obstetric indications when postnatal resuscitation and life-supporting care are planned.
- Delivery at a tertiary center is preferred when neonatal resuscitation, subspecialty care, or immediate postnatal procedures are anticipated.
- Placental pathology, cord blood studies, and fetal/neonatal autopsy or postmortem genetic testing should be considered when diagnosis remains uncertain or neonatal death occurs.
EMR-ready impression template
Hydrops / fetal effusion counseling: Ultrasound demonstrates [single effusion / hydrops fetalis with fluid in two or more compartments: ____]. Hydrops fetalis is not a diagnosis itself but a finding with a broad differential, including red-cell alloimmunization, fetal anemia, cardiac structural or rhythm disease, infection, genetic/syndromic disorders, lymphatic abnormalities, thoracic or placental masses, and monochorionic twin complications when applicable. Evaluation includes repeat maternal antibody screen, detailed fetal/placental ultrasound, MCA Doppler for fetal anemia, fetal echocardiography, targeted maternal laboratory and infectious testing, and diagnostic genetic testing with chromosomal microarray ± karyotype. If initial testing is nondiagnostic and no other etiology is identified, exome or genome sequencing was discussed/offered. Maternal risks, including mirror syndrome/preeclampsia-like disease, were reviewed. Management and delivery timing are individualized by etiology, gestational age, fetal status, maternal status, available fetal therapy, and neonatal resuscitation goals.
References and guideline links
- Society for Maternal-Fetal Medicine; Sparks TN, Norton ME, SMFM Publications Committee. Society for Maternal-Fetal Medicine Consult Series #75: Evaluation and management of non-immune hydrops fetalis. Pregnancy. 2026;2:e70208. doi:10.1002/pmf2.70208. Also available through SMFM Publications.
- Norton ME, Chauhan SP, Dashe JS; Society for Maternal-Fetal Medicine. Society for Maternal-Fetal Medicine Clinical Guideline #7: Nonimmune hydrops fetalis. Am J Obstet Gynecol. 2015;212(2):127-139. PubMed. Replaced by SMFM Consult Series #75.
- Dashe JS, Pressman EK, Hibbard JU; Society for Maternal-Fetal Medicine. SMFM Consult Series #46: Evaluation and management of polyhydramnios. Am J Obstet Gynecol. 2018;219(4):B2-B8. doi:10.1016/j.ajog.2018.07.016.
- Battarbee AN, Osmundson SS, McCarthy AM, Louis JM; Society for Maternal-Fetal Medicine Publications Committee. SMFM Consult Series #71: Management of previable and periviable preterm prelabor rupture of membranes. Am J Obstet Gynecol. 2024;231(4):B2-B15. doi:10.1016/j.ajog.2024.07.016.
- American College of Obstetricians and Gynecologists. Prediction and Prevention of Spontaneous Preterm Birth: ACOG Practice Bulletin, Number 234. Obstet Gynecol. 2021;138(2):e65-e90. doi:10.1097/AOG.0000000000004479.
- Santo S, Mansour S, Thilaganathan B, Homfray T, Papageorghiou A, Calvert S, Bhide A. Prenatal diagnosis of non-immune hydrops fetalis: what do we tell the parents? Prenat Diagn. 2011;31(2):186-195. doi:10.1002/pd.2677.
- Lim FY, Zsengeller ZK, Stillman IE, Rana S. Placental origins of angiogenic dysfunction in mirror syndrome. Hypertens Pregnancy. 2012;31(2):211-217. doi:10.3109/10641955.2011.638959.
- Swanson K, Norton ME, Downum SL, Gonzalez-Velez JM, Sparks TN. Understanding preterm birth in pregnancies complicated by nonimmune hydrops fetalis. Am J Perinatol. 2023;40(9):917-922. doi:10.1055/a-2008-2495.
- Whybra C, Källén K, Hansson SR, Gunnarsson R. Non-immune hydrops fetalis was rare in Sweden during 1997–2015, but cases were associated with complications and poor prognosis. Acta Paediatr. 2020;109(12):2570-2577. doi:10.1111/apa.15260.
- Society for Maternal-Fetal Medicine. Evaluation and management of non-immune hydrops fetalis: visual summary. SMFM visual PDF.
Disclaimer: This page is for educational use by clinicians and does not replace individualized medical judgment, local protocols, or consultation with maternal-fetal medicine, genetics, fetal cardiology, fetal therapy, neonatology, or other specialists as indicated.